Senores Pharma: Choice Equities Sees Strong Growth, Lifts Target to Rs 1045

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Senores Pharma: Choice Equities Sees Strong Growth, Lifts Target to Rs 1045
Overview

Choice Institutional Equities has reiterated a BUY rating on Senores Pharma, boosting its target price to Rs 1045. The brokerage highlights the company's strong growth phase, fueled by an expanding product pipeline in regulated and emerging markets, coupled with ongoing geographical reach. Faster-than-expected EBITDA margin expansion, driven by proprietary product contributions and backward integration, underpins the positive outlook, with revised revenue and PAT growth estimates for FY26E.

Senores Pharma is navigating a significant growth trajectory, prompting Choice Institutional Equities to maintain its BUY recommendation and revise the stock's price target upwards to Rs 1045. This optimistic outlook is underpinned by a robust product launch pipeline, featuring 28 Abbreviated New Drug Applications (ANDAs) targeting regulated markets and an expansive 450-product portfolio for emerging markets projected over the next four to eight quarters.

Pipeline and Expansion Drive Growth

The company's strategy of increasing the contribution from its own branded products across various regions is yielding strong results. Simultaneously, aggressive backward integration efforts are proving more effective than anticipated. These initiatives have collectively accelerated EBITDA margin expansion, a key metric for profitability, exceeding previous expectations.

Margin and Revenue Forecasts

Choice Institutional Equities now forecasts Senores Pharma's EBITDA margin to reach 29.0%, aligning with the management's latest guidance and a notable increase from the prior 24-26% projection. Revenue growth is still anticipated to surpass 50%, while Profit After Tax (PAT) is expected to double, achieving 100% growth for the fiscal year 2026 estimates. Reflecting this improved margin outlook, the brokerage has adjusted its earnings estimates upwards by 3.6% for FY26E and 3.1% for FY27E.

Valuation and Target Price

The stock is valued at 30 times the average estimated Earnings Per Share (EPS) for FY27-FY28, a multiple supported by a Price/Earnings to Growth (PEG) ratio of 0.61x. This conservative valuation, coupled with the company's strong fundamentals, justifies the BUY rating and the revised target price of Rs 1045, up from Rs 1010 previously. The analysis suggests significant upside potential for investors.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.